EMA starts assessment of Bavarian Nordic's monkeypox vaccine

The European Medicines Agency (EMA) will investigate whether Imvanex, which is already approved for smallpox, can be authorized within the monkeypox indication.

Bavarian Nordic/PR | Photo: LUKAS BARTH/REUTERS / X03379

The EMA has decided to investigate whether Bavarian Nordic’s approved smallpox vaccine Imvanex should also be approved within the monkeypox indication without waiting for an indication expansion application, the authority reveals on its website.

The vaccine is already approved within smallpox and monkeypox in the US under the name of Jynneos, and in Canada under the name Imvamune. Furthermore, several European countries have administered the vaccine off-label within the monkeypox indication.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs